Download PDF
Tierarztl Prax Ausg K Kleintiere Heimtiere 2020; 48(06): 420-432
DOI: 10.1055/a-1274-9268
Übersichtsartikel

GnRH-Agonisten in der Kleintierpraxis – Was wissen wir 13 Jahre nach der EU-Zulassung?

GnRH agonist implants in small animal practice – what do we know 13 years following EU registration?
Sabrina Stempel
,
Sandra Goericke-Pesch
Reproduktionsmedizinische Einheit der Kliniken – Abteilung Kleintier, Stiftung Tierärztliche Hochschule Hannover, Hannover
› Author Affiliations
› Further Information
    Permissions and Reprints

Zusammenfassung

Die Verfügbarkeit von GnRH-Agonist-Implantaten bietet die Möglichkeit der reversiblen, temporären Downregulation der endokrinen und germinativen Hodenfunktion bei Rüden und Frettchenrüden. Diese Übersichtsarbeit liefert einen Überblick über die zugelassene Indikation, Erzielung einer vorübergehenden Unfruchtbarkeit bei gesunden, unkastrierten, geschlechtsreifen Rüden (4,7 und 9,4 mg Deslorelin) und Frettchenrüden (9,4 mg Deslorelin) sowie über verschiedene Off-Label-Indikationen. Die Off-Label-Anwendung erfordert eine strenge Indikationsstellung, Besitzeraufklärung und einen Therapienotstand. Off-Label-Indikationen beim Rüden sind sexualhormonabhängiges (störendes) Verhalten, benigne Prostatahyperplasie, Adenome der perinealen Drüsen und Alopezie X. Die Anwendung erfolgt beim Frettchen zur Unterdrückung der Fertilität und des Zyklus, aber auch zur medikamentösen Therapie des Hyperadrenokortizismus. Bei Katze und Kater kann ebenso eine Unterdrückung der Fortpflanzung induziert werden. Problematisch sind hier insbesondere der variable Wirkeintritt und die unterschiedliche, z. T. sehr lange Wirkdauer. Während kein (ausreichend) kontrazeptiver Effekt bei männlichen Kaninchen und Meerschweinchen nachgewiesen wurde, kann das Implantat den Zyklus bei weiblichen Kaninchen und Meerschweinchen sowie die Reproduktion bei Ratten beiderlei Geschlechts unterdrücken. Bei Vögeln und Reptilien bestehen signifikante speziespezifische Unterschiede hinsichtlich Wirksamkeit, Wirkeintritt und Wirkdauer. Ein erfolgreicher Einsatz ist bei Huhn, Japanwachtel und Psittaziden hinsichtlich Verhinderung der Eiablage beschrieben, bei Tauben kommt es nur zur Reduktion der Eiablage. Berichte zum erfolgreichen Einsatz bei reproduktionsassoziierten Verhaltensproblemen (Federpicken, Aggressivität) liegen ebenfalls vor. Bei männlichen Tieren einzelner Vogelspezies (Japanwachtel, Zebrafink) bewirkt das Deslorelin-Implantat eine Reduktion der Testosteronkonzentration. Therapeutisch ist der erfolgreiche Einsatz beim Wellensittich mit hormonproduzierendem Sertoli-Zell-Tumor sowie beim Truthahn zur Verhaltensmodulation und Haltungserleichterung (Reduktion der Aggression) beschrieben. Bei Leguanen unterdrückt das Implantat die Ovaraktivität.

Abstract

The availability of GnRH agonist implants offers the possibility of a reversible, temporary downregulation of endocrine and germinative testicular function in male dogs and hobs. This review provides an overview of the registered indication, the induction of temporary infertility in healthy, intact, sexually mature male dogs (4.7 and 9.4 mg deslorelin) and hobs (9.4 mg deslorelin) as well as various off-label indications. Off-label use requires strict indications, informed consent from the owner and a lack of licensed medication (safe and optimum effect). Off-label indications in the male dog include sexual-hormone dependant (disturbing) behavior, benign prostatic hyperplasia, small adenomas of the hepatoid glands and alopecia X. Successful use of deslorelin implants for estrus suppression in jils, but also for the treatment of hyperadrenocorticism in ferrets in general have been described. Similarly, hormonal castration can be induced in tomcats and queens. The variable time to onset of effect and its duration (extremely variable in some animals) represent a challenge for breeders. No (sufficient) contraceptive activity was identified in male rabbits and male guinea pigs; however, treatment did successfully suppress the estrus cycle in female individuals of these species, as well as reproductive activity in male and female rats. Regarding the use in birds and reptiles, significant species-specific differences exist with regard to efficacy, time until onset of effect and duration of downregulation. In birds, the implant is efficient to fully suppress egg laying in chicken, Japanese quail and psittacids. In doves, egg laying is only significantly reduced. Successful treatment of reproduction-associated (unwanted) behaviour patterns (feather picking, aggression) has also been described. In some male birds, namely zebrafinch and Japanese quail, the deslorelin implant is suitable to reduce testosterone levels. Successful treatment of hormone-dependent tumours (Sertoli-cell tumorus) in budgerigars has been described as well as the modulation of specific behavior in turkeys and an efficacy in facilitating their keeping (i. e. reduction of aggression). In reptiles, only the successful use of deslorelin in iguana has been demonstrated to date.

Schlüsselwörter

Testkastration - Deslorelin - GnRH-Agonist-Implantat - Kleintier - Exoten - Fertilitätsunterdrückung

Key words

Test castration - deslorelin - GnRH-agonist implant - small animals - exotic animals - fertility suppression


Publication History

Received: 11 August 2020

Accepted: 29 October 2020

Article published online:
04 December 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Society for Theriogenology. Basis for Position on Mandatory Spay-Neuter in the Canine and Feline. https://cdn.ymaws.com/www.therio.org/resource/resmgr/docs/spay-neuter_basis.pdf Stand: 25. Oktober 2020
    PubMedGoogle Scholar
  • 2 Hegstad Kallehauge M, Drost Horn C. Expectations of Scandinavian veterinarians and dog owners about effects of neutralisation [Masterarbeit]. Universität Kopenhagen; 2017
    Google Scholar
  • 3 Wongsaengchan C, McKeegan DEF. The Views of the UK Public Towards Routine Neutering of Dogs and Cats. Animals (Basel) 2019; 9 doi:10.3390/ani9040138
    PubMedGoogle Scholar
  • 4 VETIDATA. Veterinärmedizinischer Informationsdienst für Arzneimittelanwendung, Toxikologie und Arzneimittelrecht. https://www.vetidata.de Stand: 23.10.2020
    PubMedGoogle Scholar
  • 5 Lange K, Cordes EK, Hoppen HO. et al. Determination of concentrations of sex steroids in blood plasma and semen of male dogs treated with delmadinone acetate or finasteride. J Reprod Fertil Suppl 2001; 57: 83-91
    PubMedGoogle Scholar
  • 6 Wright PJ, Stelmasiak T, Black D. et al. Medroxyprogesterone acetate and reproductive processes in male dogs. Aust Vet J 1979; 55: 437-438 doi:10.1111/j.1751–0813.1979.tb05602.x
    CrossrefPubMedGoogle Scholar
  • 7 Günzel-Apel AR, Bostedt H. Reproduktionsmedizin und Neonatologie von Hund und Katze. 1. Aufl.. Stuttgart: Schattauer; 2016. DOI: doi:10.1055/b-005–148982
    CrossrefGoogle Scholar
  • 8 Frank DW, Kirton KT, Murchison TE. et al. Mammary Tumors and Serum Hormones in the Bitch Treated With Medroxyprogesterone Acetate or Progesterone for Four Years. Fertil Steril 1979; 31 (03) 340-346 doi:10.1016/s0015–0282(16)43886–0
    CrossrefPubMedGoogle Scholar
  • 9 Concannon P, Altszuler N, Hampshire J. et al. Growth Hormone, Prolactin, and Cortisol in dogs Developing Mammary Nodules and an Acromegaly-Like Appearance during Treatment with medroxyprogesterone Acetate. The Endocrine Society. 1980 106. (4). doi:10.1210/endo-106–4-1173
    PubMedGoogle Scholar
  • 10 Koch H. 10 Jahre retrospektiver Betrachtung über die Anwendung von Medroxyprogesteronacetat bei Kleintieren. Kleintierprax 1989; 34: 141-188
    PubMedGoogle Scholar
  • 11 Kooistra HS, Okkens AC. Secretion of prolactin and growth hormone in relation to ovarian activity in the dog. Reprod Domest Anim 2001; 36 (03/04) 115-119
    CrossrefPubMedGoogle Scholar
  • 12 Ficus H-J, Jöchle W. Erwünschte und unerwünschte Gestagenwirkungen bei der Hündin. Tierarztl Prax 1975; 3: 231-241
    PubMedGoogle Scholar
  • 13 Kempker K, Gussow A, Neiger R. [Transient, secondary hypoadrenocorticism after treatment with delmadinone acetate (Tardastrex®) in a two year old male dog]. Schweiz Arch Tierheilkd 2016; 158: 193-197 doi:10.17236/sat00056
    CrossrefPubMedGoogle Scholar
  • 14 Arlt S. Die hormonelle Kastration von Rüde und Hündin – ein Überblick. Veterinärspiegel 2010; 20 (04) 155-160 doi:10.1055/s-0030–1250537
    PubMedGoogle Scholar
  • 15 Padula AM. GnRH analogues – agonists and antagonists. Anim Reprod Sci 2005; 88: 115-126 doi:10.1016/j.anireprosci.2005.05.005
    CrossrefPubMedGoogle Scholar
  • 16 Junaidi A, Williamson PE, Cummins JM. et al. Use of a new drug delivery formulation of the gonadotrophin-releasing hormone analogue Deslorelin for reversible long-term contraception in male dogs. Reprod Fertil Dev 2003; 15: 317-322 doi:10.1071/RD03039
    CrossrefPubMedGoogle Scholar
  • 17 Junaidi A, Williamson PE, Martin GB. et al. Dose-response studies for pituitary and testicular function in male dogs treated with the GnRH superagonist, deslorelin. Reprod Domest Anim 2009; 44: 725-734 doi:10.1111/j.1439–0531.2008.01060.x
    CrossrefPubMedGoogle Scholar
  • 18 Junaidi A, Williamson PE, Martin GB. et al. Pituitary and testicular endocrine responses to exogenous gonadotrophin-releasing hormone (GnRH) and luteinising hormone in male dogs treated with GnRH agonist implants. Reprod Fertil Dev 2007; 19: 891-898 doi:10.1071/rd07088
    CrossrefPubMedGoogle Scholar
  • 19 Romagnoli S, Siminica A, Sontas BH. et al. Semen quality and onset of sterility following administration of a 4.7-mg deslorelin implant in adult male dogs. Reprod Domest Anim 2012; 47 (Suppl. 06) 389-392 doi:10.1111/rda.12058
    CrossrefPubMedGoogle Scholar
  • 20 Schoemaker NJ, van Deijk R, Muijlaert B. et al. Use of a gonadotropin releasing hormone agonist implant as an alternative for surgical castration in male ferrets (Mustela putorius furo). Theriogenology 2008; 70: 161-167 doi:10.1016/j.theriogenology.2008.03.006
    CrossrefPubMedGoogle Scholar
  • 21 Grosset C, Peters S, Peron F. et al. Contraceptive Effect and Potential Side-Effects of Deslorelin Acetate Implants in Rats (Rattus Norvegicus): Preliminary Observations. Can J Vet Res 2012; 76 (03) 209-214
    PubMedGoogle Scholar
  • 22 Ludwig C, Desmoulins PO, Driancourt MA. et al. Reversible downregulation of endocrine and germinative testicular function (hormonal castration) in the dog with the GnRH-agonist azagly-nafarelin as a removable implant „Gonazon“; a preclinical trial. Theriogenology 2009; 71: 1037-1045 doi:10.1016/j.theriogenology.2008.10.015
    CrossrefPubMedGoogle Scholar
  • 23 Riesenbeck A, Klein R, Hoffmann B. Downregulation, eine neue, reversible Möglichkeit zur Ausschaltung der Hodenfunktion beim Rüden. Prakt Tierarzt 2002; 83 (86) 512-520
    Google Scholar
  • 24 Goericke-Pesch S, Ludwig C, Hoffmann B. Development of semen quality following reversible downregulation of testicular function in male dogs with a GnRH agonist implant. Reprod Domest Anim 2012; 47: 625-628 doi:10.1111/j.1439–0531.2011.01933.x
    CrossrefPubMedGoogle Scholar
  • 25 Gunzel-Apel AR, Seefeldt A, Eschricht FM. et al. Effects of gonadectomy on prolactin and LH secretion and the pituitary-thyroid axis in male dogs. Theriogenology 2009; 71: 746-753 doi:10.1016/j.theriogenology.2008.09.047
    CrossrefPubMedGoogle Scholar
  • 26 Rispoli LA, Nett TM. Pituitary gonadotropin-releasing hormone (GnRH) receptor: structure, distribution and regulation of expression. Anim Reprod Sci 2005; 88: 57-74 doi:10.1016/j.anireprosci.2005.05.004
    CrossrefPubMedGoogle Scholar
  • 27 Trigg TE, Doyle AG, Walsh JD. et al. A review of advances in the use of the GnRH agonist deslorelin in control of reproduction. Theriogenology 2006; 66: 1507-1512 doi:10.1016/j.theriogenology.2006.02.037
    CrossrefPubMedGoogle Scholar
  • 28 Polisca A, Orlandi R, Troisi A. et al. Clinical efficacy of the GnRH agonist (deslorelin) in dogs affected by benign prostatic hyperplasia and evaluation of prostatic blood flow by Doppler ultrasound. Reprod Domest Anim 2013; 48: 673-680 doi:10.1111/rda.12143
    CrossrefPubMedGoogle Scholar
  • 29 Junaidi A, Williamson PE, Trigg TE. et al. Morphological study of the effects of the GnRH superagonist deslorelin on the canine testis and prostate gland. Reprod Domest Anim 2009; 44: 757-763 doi:10.1111/j.1439–0531.2008.01066.x
    CrossrefPubMedGoogle Scholar
  • 30 Goericke-Pesch S, Wilhelm E, Ludwig C. et al. Evaluation of the clinical efficacy of Gonazon implants in the treatment of reproductive pathologies, behavioral problems, and suppression of reproductive function in the male dog. Theriogenology 2010; 73: 920-926 doi:10.1016/j.theriogenology.2009.11.018
    CrossrefPubMedGoogle Scholar
  • 31 De Gier J, Vinke CM. Use of deslorelin to control hypersexuality in male dogs. Proceedings of the 7th EVSSAR congress; Louvain-la-Neuve: 2010: 9-11
    Google Scholar
  • 32 De Gier J, Okkens AC, Oei CHY. et al. Behaviour and the pituitary-testicular axis in dogs before and after surgical or chemical castration with the GnRH agonist deslorelin. 7th ISCFR and 15th EVSSAR Congress; 2012
    Google Scholar
  • 33 Neilson JC, Eckstein RA, Hart BL. Effects of castration on problem behaviors in male dogs with reference to age and duration of behavior. J Am Vet Med Assoc 1997; 211 (02) 180-182
    PubMedGoogle Scholar
  • 34 Trigg TE, Wright PJ, Armour AF. et al. Use of a GnRH analogue implant to produce reversible long-term suppression of reproductive function in male and female domestic dogs. J Reprod Fertil Suppl 2001; 57: 255-261
    PubMedGoogle Scholar
  • 35 Goericke-Pesch S, Spang A, Schulz M. et al. Recrudescence of spermatogenesis in the dog following downregulation using a slow release GnRH agonist implant. Reprod Domest Anim 2009; 44 (Suppl. 02) 302-308 doi:10.1111/j.1439–0531.2009.01378.x
    CrossrefPubMedGoogle Scholar
  • 36 Goericke-Pesch S, Gentil M, Spang A. et al. Status of the down-regulated canine testis using two different GNRH agonist implants in comparison with the juvenile testis. Reproduction 2013; 146: 517-526 doi:10.1530/REP-13–0195
    CrossrefPubMedGoogle Scholar
  • 37 Goericke-Pesch S. Alternativen zur chirurgischen Kastration bei Hunden, Katzen und kleinen Heimtieren. Kleintierprax 2016; 61: 657-665
    PubMedGoogle Scholar
  • 38 Sirivaidyapong S, Mehl NS, Trigg TE. Delay of puberty and reproductive performance in male dogs following the implantation of 4.7 and 9.4 mg GnRH-agonist deslorelin at an early pre-pubertal age. Reprod Domest Anim 2012; 47 (Suppl. 06) 400-402 doi:10.1111/rda.12066
    CrossrefPubMedGoogle Scholar
  • 39 Goericke-Pesch S, Wilhelm E, Hoffmann B. Hormonelle Downregulation der Hodenfunktion bei Rüde und Kater; eine retrospektive Studie. PraktTierarzt 2010; 91: 563-570
    PubMedGoogle Scholar
  • 40 Albanese F, Malerba E, Abramo F. et al. Deslorelin for the treatment of hair cycle arrest in intact male dogs. Vet Dermatol 2014; 25: 519-522 doi:10.1111/vde.12148
    CrossrefPubMedGoogle Scholar
  • 41 Layne EA, Richmond RV. Deslorelin Implant Treatment for Hair Cycle Arrest (Alopecia X) in Two Intact Male Keeshonden. J Am Anim Hosp Assoc 2018; 54: 231-234 doi:10.5326/JAAHA-MS-6646
    CrossrefPubMedGoogle Scholar
  • 42 Goericke-Pesch S. Kryptorchismus bei Hund und Katze. Kleintierprax 2010; 55: 255-261
    PubMedGoogle Scholar
  • 43 Gentil M, Hoffmann B, Spang A. et al. Restart of steroidogenesis in dogs during recrudescence of testicular function following downregulation with a GnRH-agonist implant. Cell Tissue Res 2012; 350: 513-523 doi:10.1007/s00441–012–1506–5
    CrossrefPubMedGoogle Scholar
  • 44 Schoemaker NJ. Gonadotrophin-Releasing Hormone Agonists and Other Contraceptive Medications in Exotic Companion Animals. Vet Clin North Am Exot Anim Pract 2018; 21: 443-464 doi:10.1016/j.cvex.2018.01.011
    CrossrefPubMedGoogle Scholar
  • 45 Vinke C, van Deijk R, Houx B. et al. The effects of surgical and chemical castration on intermale aggression, sexual behaviour and play behaviour in the male ferret (Mustela putorius furo). Appl Anim Behav Sci 2008; 115: 104-121
    CrossrefPubMedGoogle Scholar
  • 46 van Zeeland YR, Pabon M, Roest J. et al. Use of a GnRH agonist implant as alternative for surgical neutering in pet ferrets. Vet Rec 2014; 175: 66 doi:10.1136/vr.102389
    CrossrefPubMedGoogle Scholar
  • 47 Wagner RA, Piche CA, Jochle W. et al. Clinical and endocrine responses to treatment with deslorelin acetate implants in ferrets with adrenocortical disease. Am J Vet Res 2005; 66: 910-914 doi:10.2460/ajvr.2005.66.910
    CrossrefPubMedGoogle Scholar
  • 48 Wagner RA, Bailey EM, Schneider JF. et al. Leuprolide acetate treatment of adrenocortical disease in ferrets. J Am Vet Med Assoc 2001; 218: 1272-1274 doi:10.2460/javma.2001.218.1272
    CrossrefPubMedGoogle Scholar
  • 49 Hawkins MG. Advances in exotic mammal clinical therapeutics. Vet Clin North Am Exot Anim Pract 2015; 18: 323-337 doi:10.1016/j.cvex.2015.01.008
    CrossrefPubMedGoogle Scholar
  • 50 Faya M, Marchetti C, Priotto M. et al. Postponement of canine puberty by neonatal administration of a long term release GnRH superagonist. Theriogenology 2018; 118: 190-195 doi:10.1016/j.theriogenology.2018.05.043
    CrossrefPubMedGoogle Scholar
  • 51 Gobello C. Prepubertal and pubertal canine reproductive studies: conflicting aspects. Reprod Domest Anim 2014; 49: e70-73 doi:10.1111/rda.12414
    CrossrefPubMedGoogle Scholar
  • 52 Jurczak A, Janowski T, Zdunczyk S. et al. Attempts to downregulate ovarian function in the bitch by applying a GnRH agonist implant in combination with a 3ss-hydroxysteroid-dehydrogenase blocker; a pilot study. Theriogenology 2020; 145: 176-180 doi:10.1016/j.theriogenology.2019.10.022
    CrossrefPubMedGoogle Scholar
  • 53 Fontaine E, Mir F, Vannier F. et al. Induction of fertile oestrus in the bitch using Deslorelin, a GnRH agonist. Theriogenology 2011; 76: 1561-1566 doi:10.1016/j.theriogenology.2011.06.031
    CrossrefPubMedGoogle Scholar
  • 54 Körber H, Wehrend A, Hoffmann B. et al. Einsatz des GnRH-Agonisten Suprelorin® zur Läufigkeitsunterdrückung bei der Hündin. Proceedings of the 59th Annual Congress of the German Society for Small Animal Medicine (DGK-DVG) Berlin; 2013: 201-202
    Google Scholar
  • 55 Körber H, Wehrend A, Hoffmann B. et al. The use of Suprelorin® for postponement of oestrus in the bitch. Proceedings of the 16th EVSSAR (European Veterinary Society for Small Animal Reproduction) Congress; Toulouse, France: 2013
    Google Scholar
  • 56 Arlt SP, Spankowsky S, Heuwieser W. Follicular cysts and prolonged oestrus in a female dog after administration of a deslorelin implant. N Z Vet J 2011; 59: 87-91 doi:10.1080/00480169.2011.552858
    PubMedGoogle Scholar
  • 57 Palm J, Reichler IM. The use of Deslorelin acetate for the suppression of heat in the bitch: A retrospective study of 102 cases. Reprod Dom Anim Suppl 2011; 46: 33
    PubMedGoogle Scholar
  • 58 Romagnoli S, Stelletta C, Milani C. et al. Clinical use of deslorelin for the control of reproduction in the bitch. Reprod Domest Anim 2009; 44 (Suppl. 02) 36-39 doi:10.1111/j.1439–0531.2009.01441.x
    CrossrefPubMedGoogle Scholar
  • 59 Sung M, Armour AF, Wright PJ. The influence of exogenous progestin on the occurrence of proestrous or estrous signs, plasma concentrations of luteinizing hormone and estradiol in deslorelin (GnRH agonist) treated anestrous bitches. Theriogenology 2006; 66: 1513-1517 doi:10.1016/j.theriogenology.2006.01.020
    CrossrefPubMedGoogle Scholar
  • 60 Palm J, Reichler IM. [The use of deslorelin acetate (Suprelorin®) in companion animal medicine]. Schweiz Arch Tierheilkd 2012; 154: 7-12 doi:10.1024/0036–7281/a000286
    CrossrefPubMedGoogle Scholar
  • 61 Piepenbrink A, Failing K, Riesenbeck A. et al. Downregulation von LH bei der Hündin nach Anwendung des GnRH-Agonisten Buserelin in Implantatform. Tierarztl Prax Ausg K Kleintiere Heimtiere 2017; 45 (03) 147-152 doi:10.15654/TPK-160790
    Article in Thieme ConnectPubMedGoogle Scholar
  • 62 Maenhoudt C, Santos NR, Fontaine E. et al. Results of GnRH agonist implants in oestrous induction and oestrous suppression in bitches and queens. Reprod Domest Anim 2012; 47 (Suppl. 06) 393-397 doi:10.1111/rda.12041
    CrossrefPubMedGoogle Scholar
  • 63 Borges P, Fontaine E, Maenhoudt C. et al. Fertility in Adult Bitches Previously Treated with a 4.7 mg Subcutaneous Deslorelin Implant. Reprod Domest Anim 2015; 50: 965-971 doi:10.1111/rda.12616
    CrossrefPubMedGoogle Scholar
  • 64 Wolf T, Meyer H, Kutzler M. Litter size response to oestrous induction with deslorelin (Ovuplant®) in dogs. Reprod Domest Anim 2012; 47 (Suppl. 06) 387-388 doi:10.1111/rda.12082
    CrossrefPubMedGoogle Scholar
  • 65 von Heimendahl A, Miller C. Clinical evaluation of deslorelin to induce oestrus, ovulation and pregnancy in the bitch. Reprod Domest Anim 2012; 47 (Suppl. 06) 398-399 doi:10.1111/rda.12080
    CrossrefPubMedGoogle Scholar
  • 66 Reichler IM, Hubler M, Jöchle W. et al. The effect of GnRH analogs on urinary incontinence after ablation of the ovaries in dogs. Theriogenology 2003; 60 (07) 1207-1216 doi:10.1016/s0093–691x(02)01368–7
    CrossrefPubMedGoogle Scholar
  • 67 Novotny R, Cizek P, Vitasek R. et al. Reversible suppression of sexual activity in tomcats with deslorelin implant. Theriogenology 2012; 78: 848-857 doi:10.1016/j.theriogenology.2012.03.035
    CrossrefPubMedGoogle Scholar
  • 68 Romagnoli S, Baldan A, Ferro S. et al. Length of efficacy and effect of implant location in adult tom cats treated with a 9.4 mg deslorelin subcutaneous implant. J Feline Med Surg 2019; 21: 507-519 doi:10.1177/1098612X18788157
    CrossrefPubMedGoogle Scholar
  • 69 Goericke-Pesch S, Georgiev P, Antonov A. et al. Clinical efficacy of a GnRH-agonist implant containing 4.7 mg deslorelin, Suprelorin, regarding suppression of reproductive function in tomcats. Theriogenology 2011; 75: 803-810 doi:10.1016/j.theriogenology.2010.10.020
    CrossrefPubMedGoogle Scholar
  • 70 Goericke-Pesch S, Georgiev P, Antonov A. et al. Reversibility of germinative and endocrine testicular function after long-term contraception with a GnRH-agonist implant in the tom-a follow-up study. Theriogenology 2014; 81: 941-946 doi:10.1016/j.theriogenology.2014.01.015
    CrossrefPubMedGoogle Scholar
  • 71 Goericke-Pesch S, Georgiev P, Fasulkov I. et al. Basal testosterone concentrations after the application of a slow-release GnRH agonist implant are associated with a loss of response to buserelin, a short-term GnRH agonist, in the tom cat. Theriogenology 2013; 80: 65-69 doi:10.1016/j.theriogenology.2013.03.010
    CrossrefPubMedGoogle Scholar
  • 72 Novotny R, Vitasek R, Bartoskova A. et al. Azoospermia with variable testicular histology after 7 months of treatment with a deslorelin implant in toms. Theriogenology 2015; 83: 1188-1193 doi:10.1016/j.theriogenology.2014.12.026
    CrossrefPubMedGoogle Scholar
  • 73 Gultiken N, Aslan S, Ay SS. et al. Effect of deslorelin on testicular function, serum dihydrotestosterone and oestradiol concentrations during and after suppression of sexual activity in tom cats. J Feline Med Surg 2017; 19: 123-131 doi:10.1177/1098612X15615381
    CrossrefPubMedGoogle Scholar
  • 74 Ferre-Dolcet L, Carniello L, Ferro S. et al. Interval between Removal of a 4.7 mg Deslorelin Implant after a 3-, 6-, and 9-Month Treatment and Restoration of Testicular Function in Tomcats. Animals (Basel) 2020; 10: 1559 doi:10.3390/ani10091559
    CrossrefPubMedGoogle Scholar
  • 75 Romagnoli S, Baldan A, Righetti C. et al. Semen quality and interval to sterility in tom cats treated with a 9.4 mg deslorelin implant. J Feline Med Surg 2017; 19: 194-199 doi:10.1177/1098612X15623985
    CrossrefPubMedGoogle Scholar
  • 76 Cecchetto M, Salata P, Baldan A. et al. Postponement of puberty in queens treated with deslorelin. J Feline Med Surg 2017; 19: 1224-1230 doi:10.1177/1098612X16688406
    CrossrefPubMedGoogle Scholar
  • 77 Risso A, Corrada Y, Barbeito C. et al. Long-term-release GnRH agonists postpone puberty in domestic cats. Reprod Domest Anim 2012; 47: 936-938 doi:10.1111/j.1439–0531.2012.01994.x
    CrossrefPubMedGoogle Scholar
  • 78 Jemmett JE, Evans JM. A survey of sexual behaviour and reproduction of female cats. J Small Anim Pract 1977; 18: 31-37 doi:10.1111/j.1748–5827.1977.tb05821.x
    CrossrefPubMedGoogle Scholar
  • 79 Povey RC. Reproduction in the pedigree female cat. A survey of breeders. Can Vet J 1978; 19 (08) 207-213
    PubMedGoogle Scholar
  • 80 Toydemir TS, Kilicarslan MR, Olgac V. Effects of the GnRH analogue deslorelin implants on reproduction in female domestic cats. Theriogenology 2012; 77: 662-674 doi:10.1016/j.theriogenology.2011.07.046
    CrossrefPubMedGoogle Scholar
  • 81 Goericke-Pesch S, Georgiev P, Atanasov A. et al. Treatment of queens in estrus and after estrus with a GnRH-agonist implant containing 4.7 mg deslorelin; hormonal response, duration of efficacy, and reversibility. Theriogenology 2013; 79: 640-646 doi:10.1016/j.theriogenology.2012.11.018
    CrossrefPubMedGoogle Scholar
  • 82 Munson L, Bauman JE, Asa CS. et al. Efficacy of the GnRH analogue deslorelin for suppression of oestrous cycles in cats. J Reprod Fertil Suppl 2001; 57: 269-273
    PubMedGoogle Scholar
  • 83 Forman C. Untersuchung zur reversiblen Fortpflanzungsunterdrückung beim Meerschweinchen [Dissertation]. Gießen: Justus-Liebig-Universität; 2017: 121
    Google Scholar
  • 84 Arlt S, Spankowski S, Kaufmann T. et al. Fertility Control in a Male Rabbit Using a Deslorelin Implant. A Case Report. World Rabbit Sci 2010; 18 (13) 179-182
    CrossrefPubMedGoogle Scholar
  • 85 Goericke-Pesch S, Groeger G, Wehrend A. The effects of a slow release GnRH agonist implant on male rabbits. Anim Reprod Sci 2015; 152: 83-89 doi:10.1016/j.anireprosci.2014.11.002
    CrossrefPubMedGoogle Scholar
  • 86 Goericke-Pesch S, Wehrend A. The use of a slow release GnRH-agonist implant in female ferrets in season for oestrus suppression. Schweiz Arch Tierheilkd 2012; 154: 487-491 doi:10.1024/0036–7281/a000392
    CrossrefPubMedGoogle Scholar
  • 87 Geyer A, Daub L, Otzdorff C. et al. Reversible estrous cycle suppression in prepubertal female rabbits treated with slow-release deslorelin implants. Theriogenology 2016; 85: 282-287 doi:10.1016/j.theriogenology.2015.09.037
    CrossrefPubMedGoogle Scholar
  • 88 Geyer A, Poth T, Otzdorff C. et al. Histopathologic examination of the genital tract in rabbits treated once or twice with a slow-release deslorelin implant for reversible suppression of ovarian function. Theriogenology 2016; 86: 2281-2289 doi:10.1016/j.theriogenology.2016.07.024
    CrossrefPubMedGoogle Scholar
  • 89 Kohutova S. Diagnostika a terapica endokrinne aktívnych reprodukcnych ochorení u morcata domáceho (Cavia aperea f. porcellus) [PhD thesis]. Brno: Czech Republic Brno University; 2016
    Google Scholar
  • 90 Cetin Y, Alkis I, Sendag S. et al. Long-term effect of deslorelin implant on ovarian pre-antral follicles and uterine histology in female rats. Reprod Domest Anim 2013; 48: 195-199 doi:10.1111/j.1439–0531.2012.02128.x
    CrossrefPubMedGoogle Scholar
  • 91 Edwards B, Smith A, Skinner DC. Dose and durational effects of the gonadotropin-releasing hormone agonist, deslorelin: the male rat (Rattus norvegicus) as a model. J  Zoo Wildl Med 2013; 44: S97-101 doi:10.1638/1042–7260–44.4 S.S97L42:URLEND
    CrossrefPubMedGoogle Scholar
  • 92 Smith AW, Asa CS, Edwards BS. et al. Predominant suppression of follicle-stimulating hormone beta-immunoreactivity after long-term treatment of intact and castrate adult male rats with the gonadotrophin-releasing hormone agonist deslorelin. J Neuroendocrinol 2012; 24: 737-747 doi:10.1111/j.1365–2826.2011.02271.x
    CrossrefPubMedGoogle Scholar
  • 93 Schuetzenhofer G, Goericke-Pesch S, Wehrend A. Effects of deslorelin implants on ovarian cysts in guinea pigs. Schweiz Arch Tierheilkd 2011; 153: 416-417 doi:10.1024/0036–7281/a000235
    CrossrefPubMedGoogle Scholar
  • 94 Prohaczik A, Kulcsar M, Trigg T. et al. Comparison of four treatments to suppress ovarian activity in ferrets (Mustela putorius furo). Vet Rec 2010; 166: 74-78 doi:10.1136/vr.c177
    CrossrefPubMedGoogle Scholar
  • 95 Elsinghorst TA, Timmermans HJ, Hendriks HG. Comparative pathology of endometrial carcinoma. Vet Q 1984; 6: 200-208 doi:10.1080/01652176.1984.9693937
    CrossrefPubMedGoogle Scholar
  • 96 Müller K. Hrsg. Heimtierskills – Praxisleitfaden zu Diagnose und Therapie bei kleinen Heimtieren. 1. Aufl.. Stuttgart: Schattauer; 2017. DOI: doi:10.1055/b-005–148996
    CrossrefGoogle Scholar
  • 97 Mans C, Pilny A. Use of GnRH-agonists for medical management of reproductive disorders in birds. Vet Clin North Am Exot Anim Pract 2014; 17: 23-33 doi:10.1016/j.cvex.2013.10.001
    CrossrefPubMedGoogle Scholar
  • 98 Bedecarrats GY, Shimizu M, Guémené D. Gonadotropin releasing hormone and their receptors in avian species. J Poultry Science 2006; 43 (43) 199-214
    CrossrefPubMedGoogle Scholar
  • 99 King JA, Millar RP. Structure of chicken hypothalamic luteinizing hormone-releasing hormone. II. Isolation and characterization J Biol Chem 1982; 257 (218) 10729-10732
    PubMedGoogle Scholar
  • 100 Miyamoto K, Hasegawa Y, Nomura M. et al. Identification of the second gonadotropin-releasing hormone in chicken hypothalamus: evidence that gonadotropin secretion is probably controlled by two distinct gonadotropin-releasing hormones in avian species. Proc Natl Acad Sci USA 1984; 81: 3874-3878 doi:10.1073/pnas.81.12.3874
    CrossrefPubMedGoogle Scholar
  • 101 Bentley GE, Moore IT, Sower SA. et al. Evidence for a novel gonadotropin-releasing hormone in hypothalamic and forebrain areas in songbirds. Brain Behav Evol 2004; 63: 34-46 doi:10.1159/000073758
    CrossrefPubMedGoogle Scholar
  • 102 Ubuka T, Bentley GE. Neuroendocrine control of reproduction in birds. Hormones Reproduction Vertebrates 2011; 4: 1 doi:10.1016/B978–0-12–374929–1.10001–0
    PubMedGoogle Scholar
  • 103 Nooan B, Johnson P, Matos D. Evaluation of egg-laying suppression effects of the GnRH agonist deslorelin in domestic chicken. Proc Annu Conf Ass Avian Vet. 2012
    PubMedGoogle Scholar
  • 104 Zeman M, Jurani M, Vyboh P. et al. Effects of chicken GNRH-I, GNRH-II and their analogs on plasma testosterone and reproduction in Japanese-quail. Biopharm J Vet Pharm 1991; 1 (04) 147-154
    PubMedGoogle Scholar
  • 105 De Wit M, Westerhof I, Pefold LM. Effect of leuprolide acetate on avian reproduction. Proceedings of the Association of Avian Veterinarians; New Orleans (LA): 2004: 73-74
    Google Scholar
  • 106 Klaphake E, Fecteau K, DeWit M. et al. Effects of leuprolide acetate on selected blood and fecal sex hormones in Hispaniolan Amazon parrots (Amazona ventrais). J Avian Med Surg 2009; 23: 253-262 doi:10.1647/2008–061R.1
    CrossrefPubMedGoogle Scholar
  • 107 Cowan ML, Martin GB, Monks DJ. et al. Inhibition of the reproductive system by deslorelin in male and female pigeons (Columba livia). J Avian Med Surg 2014; 28: 102-108 doi:10.1647/2013–027
    CrossrefPubMedGoogle Scholar
  • 108 Petritz OA, Sanchez-Migallon Guzman D, Paul-Murphy J. et al. Evaluation of the efficacy and safety of single administration of 4.7-mg deslorelin acetate implants on egg production and plasma sex hormones in Japanese quail (Coturnix coturnix japonica). Am J Vet Res 2013; 74: 316-323 doi:10.2460/ajvr.74.2.316
    CrossrefPubMedGoogle Scholar
  • 109 Schmidt F, Legier M, Einspanier A. et al. Influence of the GNRH slow release agonist deslorelin on gonadal activity of the Japanese quail. 1st International Conference on Avian, Herpetological and Exotic Mammal Medicine ; Wiesbaden: April 20–26 2013: 501-502
    Google Scholar
  • 110 Petritz OA, Guzman DS, Hawkins MG. et al. Evaluation of deslorelin acetate implant dosage on egg production and plasma progesterone in Japanese quail (Coturnix coturnix japonica). Proc Annu Conf Associ Avian Vet 2013; 17
    PubMedGoogle Scholar
  • 111 Summa NM, Guzman DS, Wils-Plotz EL. et al. Evaluation of the effects of a 4.7-mg deslorelin acetate implant on egg laying in cockatiels (Nymphicus hollandicus). Am J Vet Res 2017; 78: 745-751 doi:10.2460/ajvr.78.6.745
    CrossrefPubMedGoogle Scholar
  • 112 Van Sant F, Sundaram A. Retrospective study of deslorelin acetate implants in clinical practice. Proc Annu Conf Associ Avian Vet. 2013
    PubMedGoogle Scholar
  • 113 Mans C, Braun JM, Feeney M. Intranasal sedation with midazolam or midazolambutorphanol in psittacine birds: a retrospective evaluation of 114 cases (2010–2012). 1st International Conference on Avian, Herpetological and Exotic Mammal Medicine; Wiesbaden: April 20–26 2013: 292
    Google Scholar
  • 114 Murphy K, Wilson DA, Burton M. et al. Effectiveness of the GnRH agonist Deslorelin as a tool to decrease levels of circulating testosterone in zebra finches. Gen Comp Endocrinol 2015; 222: 150-157 doi:10.1016/j.ygcen.2015.09.014
    CrossrefPubMedGoogle Scholar
  • 115 Straub J, Zenker I. First experience in hormonal treatment of sertoli cell tumors in budgerigars (M. undulates) with absorbable extended release GnRH Chips (Suprelorin®). 1st International Conference on Avian, Herpetological and Exotic Mammal Medicine; Wiesbaden: April 20–26 2013: 299-301
    Google Scholar
  • 116 Molter CM, Fontenot DK, Terrell SP. Use of Deslorelin Acetate Implants to Mitigate Aggression in Two Adult Male Domestic Turkeys (Meleagris gallopavo) and Correlating Plasma Testosterone Concentrations. J Avian Med Surg 2015; 29: 224-230 doi:10.1647/2014–041
    CrossrefPubMedGoogle Scholar
  • 117 Rowland MN. Use of a deslorelin implant to control aggression in a male bearded dragon (Pogona vitticeps). Vet Rec 2011; 169: 127 doi:10.1136/vr.d2007
    CrossrefPubMedGoogle Scholar
  • 118 Potier R, Monge E, Loucachevsky T. et al. Effects of deslorelin acetate on plasma testosterone concentrations in captive yellow-bellied sliders (Trachemys scripta sp.). Acta Vet Hung 2017; 65: 440-445 doi:10.1556/004.2017.041
    CrossrefPubMedGoogle Scholar